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Abstract 
The  frequency  of  p53  and  Bcl-2  protein
expression  in  100  newly  diagnosed  and  10
relapsed  acute  myeloid  leukemia  (AML)
patients  was  analyzed  by  immunocytochem-
istry  (ICC).  The  Kaplan-Meier  method  was
used for univariate and multivariate statistical
analysis  to  assess  the  relationship  between
p53,  Bcl-2  and  clinico-hematologic  feature
with  respect  to  overall  survival  (OS)  using
SPSS statistical software. No statistical signif-
icance  was  found  in  univariate  analysis
(P=0.60).  However,  when  the  subgroups  of
patients (+1, +2, +3 and +4) were compared,
expression of p53 and Bcl-2 protein (1-10%, 11-
30%, 31-50% and >50%) was statistically sig-
nificant  (P<0.05).  However,  in  multivariate
analysis, p53, immunopositivity was independ-
ently associated with a shorter overall survival
(OS) (P=0.038) while Bcl-2 immunopositivity
was  associated  with  longer  overall  survival
(OS) (P=0.002). Our finding shows that p53
and Bcl-2 protein overexpression is a strong
indicator  of  response  to  chemotherapy  and
overall survival. This study reports for the first
time AML in patients from Eastern India. 
Introduction
Mutation of the p53 gene has been found in
a wide variety of neoplastic diseases and func-
tions as a specific transcriptional gene activa-
tor1 controlling the G1 check point of the cell
cycle, DNA repair, synthesis and apoptosis.2-5
Mutations of the p53 gene are the most com-
mon  genetic  alteration  in  human  cancer.2,6
The wild-type p53 protein has a short half-life
and cannot be detected by immunocytochem-
istry in cells. Mutated p53 on the other hand,
has a prolonged half-life and can be detectable
by immunocytochemistry. Mutation of the p53
gene  has  been  reported  in  only  5-10%  of
patients  with  acute  myeloid  leukemia  but
when present is associated with a low com-
plete  remission  rate,  early  relapse  and  poor
survival.7-10 Accumulation of altered p53 pro-
tein has been reported to be an indicator of
poor  prognosis.2-5 The  Bcl-2  gene,  the  first
member of a rapidly expanding family of genes
that  inhibit  apoptosis,  was  initially  isolated
from the t (14; 18) chromosomal translocation
found in human B-cell lymphoma.11 Relatively
high  levels  of  Bcl-2  protein  have  been
expressed in 20% of patients with AML.12 Bcl-2
is the best characterized of the proteins and its
role in the pathogenesis and prognosis of AML
has been studied with conflicting results.13-16
These studies have found that patients with
higher levels of Bcl-2 have a lower remission
rate, an inferior survival or both13,14 and, in
contrast, the patients who do not express Bcl-2
had  low  remission  rates  and  higher  relapse
rates than those with intermediate levels of
Bcl-2.15,16
Several  studies  indicate  that  the  protein
expression  levels  of  Bcl-2  determine  the  in
vitro sensitivity  of  leukemic  cells  to
chemotherapeutic drugs. A high level of Bcl-2
protein confers a survival advantage on B cells
by inhibiting apoptosis and may block a com-
mon cell death pathway induced by chemother-
apy.  High  levels  of  Bcl-2  expression  confer
resistance to apoptosis induced by chemother-
apeutic  drugs  and  association  of  Bcl-2  with
poor prognosis in AML patients and other types
of cancer.12,17-20 Bcl-2 protein expression has
been shown to predict poor outcome in acute
myeloid leukemia but conflicting results have
been reported for ALL.21-23 In the present study,
we examined specifically the protein expres-
sion of p53 and Bcl-2 in de novo acute myeloid
leukemia patients before treatment and corre-
lated their clinical and hematologic parame-
ters to overall survival (OS). 
Materials and Methods
Patients
This  study  includes  100  de  novo  and  10
relapsed de novo AML patients diagnosed in
the Department of Clinical Hematology, S.C.B.
Medical College, Cuttack, India. Diagnosis and
classification  of  AML  was  made  using  the
French-American-British  (FAB)  classification
after  conventional  cytochemical  stains  and
surface marker analysis. 
Peripheral blood monocyte isola-
tion
Using heparin as an anti-coagulant, 3 ml of
blood were collected from AML patients. The
heparinized blood was diluted in 3 ml of sterile
PBS (pH 7.4). The PBS mixed blood was placed
on  a  Ficoll  Hypaque  layer  (density  1.077
gm/m2) in a 15 mL centrifuge tube; the propor-
tion  between  the  Ficoll  Hypaque  layer  and
blood should be 1:3 and 2:3, respectively. After
centrifugation for 1,500 rpm for 30 min, the
middle layer, which contains lymphocytes and
blast cells, was collected without touching the
Ficoll  Hypaque  layer.  The  lymphocytes  were
diluted with 1 ml PBS, and then washed twice
in 1ml PBS. 
Immunocytochemistry
Both p53 and Bcl-2 immunostained samples
were taken from 5 positive controls and 5 neg-
ative controls. Lymphocyte fixations were per-
formed in methanol. These slides were incu-
bated for 10 min in 1.5% hydrogen peroxide.
After  rinsing  in  distilled  water  and  TBS
(pH=7.6), the slides were incubated with 1%
blocking buffer (BSA) in TBS (pH=7.6) for 20
min  to  suppress  the  non-specific  binding  of
immunoglobulin.  Specific  immunostaining
was evaluated by means of overnight incuba-
tion at 4°C with the appropriate primary anti-
body (PAB 240, Calbiochem, USA) which can
recognize both wild- and mutant type p53 pro-
tein  in  1:100  dilutions.  Mouse  monoclonal
antibody (Bcl2) was used to detect Bcl-2 pro-
teins. The mouse monoclonal antibody (IgG1)
Bcl-2, clone 124, is raised against an epitope
between amino acid 41 and 54 of the Bcl-2 pro-
tein  (1:100;  Dako  Corporation,  Denmark).
After washing in TBS, a secondary biotinylated
goat  anti-mouse/rabbit  antibody  (Dako
Corporation,  Denmark)  was  applied  for  30
min. Slides were rinsed with TBS and incubat-
ed with streptavidin for 30 min. The peroxi-
dase reaction was performed by incubating for
20  min  in  a  developing  solution  containing
diaminobenzedine (Sigma, USA). Finally, the
slides were rinsed in TBS and then counter-
stained with hematoxylin. The blast cells and
lymphocytes have been differentiated accord-
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ing to their morphological appearance; blast
cells are larger in size with a more prominent
nucleus than the smaller size lymphocytes. At
least 1,000 cells were counted and the results
were expressed as the percentage of positive
cells. Slides were scored as immunonegative if
no leukemic cells stained. Slides were scored
as +1 (1-10%), +2 (11-30%), +3 (31-50%) and
+4 (>50% positive cells).25,24
Statistical analysis
Univariate  analysis  was  performed  using
the Kaplan-Meier method.26 The difference in
survival between groups was evaluated by the
log rank test. Multivariate analysis was per-
formed using Cox's regression method27 with
stepwise  forward  selection  of  independent
variables based on the likelihood ratio. P<0.05
was considered statistically significant.
Results
Immunostaining for p53 and Bcl-2 was suc-
cessful in 110 AML patients. Patients’ clinical
characteristics are listed in Table 1.
Expression of p53 and Bcl-2 is het-
erogeneous in all-FAB types
A  broad  range  of  p53  and  Bcl-2  protein
expression  was  seen  in  FAB  types  (M1-M5)
and in none of the patients with M6 and M7
FAB types, as shown in Table 1. There was a
statistical difference in dispersion of p53 and
Bcl-2  protein  expression.  Ten  of  the  110
patients  had  died  at  the  time  of  analysis.
Statistical analysis strongly indicated that Bcl-
2  had  a  higher  threshold  effect  on  survival
than p53.
p53 expression and survival
Among the 110 patients, 100 (91%) patients
were  p53  immunopositive  while  10  (9%)
patients were p53 immunonegative. Of the p53
immunopositive  cases,  6  (5%)  contained  1-
10%  of  p53-positive  cells,  22  (20%)  had  11-
30%, 16 (14%) had 31-50% and 56 (51%) had
highly  expressed,  i.e.  more  than  50%,  p53
immunopositive leukemic cells. The relation-
ship between p53 and Bcl-2 protein expression
for the cut off used for scoring is shown in
Table 2. We compared the p53-immunostain-
ing  results  with  the  clinical  outcome  of
patients.  The  number  of  patients  with  p53
immunonegative (n=10) had a longer survival
rate. However, a comparison of the p53-posi-
tive vs negative subgroup (Figure 1A) failed to
reach statistical significance (P=0.60, log rank
test). Kaplan-Meier curves showed that overall
survival was shorter in subgroups +3 and +4
than in subgroups +1 and +2. There was a sta-
tistically significant difference in clinical out-
come  between  the  patient  subgroups  (+3
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Figure 1. (A) Kaplan-Meier survival curve
showing survival functions with p53 posi-
tive versus p53 negative. (B) Kaplan-Meier
survival curve showing survival functions
with Bcl-2 positive versus Bcl-2 negative.
Table 1. Patients’ characteristics according to P53 and BCL-2 immunostaining (n=110).
Parameter N.  patients Category N. p53 +ve p53 -ve P value Bcl 2+ve Bcl 2-ve P value
Sex 110 Female  42 (38.18) 38 (90.4) 4 (9.5) NS 34 (80.95) 8 (19.04) NS
Male 68 (61.81) 62 (91.17) 6 (91.17) 62 (91.17) 6 (8.82)
Age 110 >2<10 year 10 (9.09) 10 (100) NIL NS 10 (100) 0 NS
>40<60  100 (90.90) 90 (90) 10 (10) 86 (86) 14 (14)
WBC at diagnosis 110 <50¥109/L 72 (65.45) 62 (86.11) 10 (13.88)
≥50¥109/L 38 (34.54) 38 (100) NIL NS 64 (88.88) 8 (11.11) NS
TPC at diagnosis 110 <50¥109/L 72 (65.45) 64 (88.88) 8 (11.11) NS 66 (91.66) 6 (8.33) NS
≥50¥109/L 38 (34.54) 36 (94.73) 2 (5.26) 30 (78.94) 8 (21.05)
Lymphodeno-pathy 110 No 74 (67.27) 66 (89.18) 8 (10.81) NS 66 (89.18) 8 (10.81) NS
Yes 36 (32.72) 34 (94.44) 2 (5.55) 30 (83.33) 6 (16.66)
Splenomegaly 110 No 68 (61.81) 64 (94.11) 4 (5.88) NS 66 (97.05) 2 (2.94) NS
Yes 42 (38.18) 36 (85.71) 6 (14.28) 30 (71.42) 12 (28.57)
Hepatomegaly 110 No 76 (69.09) 66 (86.84) 10 (13.15) NS 72 (94.73) 4 (5.26) NS
Yes 34 (30.90) 34 (100) NIL 24 (70.58) 10 (29.41)
Mediastinal Mass 110 No 98 (89.09) 90 (91.83) 8 (8.16) NS 88 (89.79) 4 (33.33) NS
Yes 12 (10.90) 10 (83.33) 2 (16.66) 8 (66.66) 10 (10.20)
Serum LDH 110 Normal  32 (29.09) 28 (87.5) 4 (12.5) NS 26 (81.25) 6 (18.75) NS
alleviated 78 (70.90) 72 (92.30) 6 (7.69) 70 (89.74) 8 (10.25)
FAB subtypes 110 M1 32 (29.09) 32 (100) 0 NS 28 (87.5) 4 (12.5) NS
M2 32 (29.09) 28 (87.5) 4 (12.5) 28 (87.5) 4 (12.5)
M3 24 (21.81) 18 (75) 6 (25) 18 (75) 6 (25)
M4 18 (16.36) 18 (75) 0 18 (100) 0
M5 4 (3.63) 4(100) 0 4 (100) 0
M6 00 0 0 0
M7 00 0 0 0
*P value denotes the significance of difference between p53 immunopositive Vs p53 immunonegative, and Bcl-2 immunopositive Vs Bcl-2 immunonegative. TPC, total platelet count; LDH, lactate dehydrogenase; FAB-
French-American-British, NS, not significant.[Hematology Reports 2011; 3:e28]
vs+4, P=0.0415; +2 vs +4, P = 0.0051; 1 vs+3;
P=0.0419; log rank test). However, there was
no statistically significant difference between
group +1 vs +2 (P=0.4999, log rank test,). In
multivariate  analysis,  considering  several
prognostic parameters such as age, sex, white
blood cells (WBC), percentage of blast cells,
splenomegaly,  hepatomegaly,  mediastinal
mass and serum LDH, immunopositivity of p53
was  associated  with  shorter  overall  survival
(P=0.038).
Among 100 p53 immunopositive patients, 9
patients died within 1-20 months (median 11)
and 91 were alive at a median follow up of 22
months  (range  1-24).  On  the  other  hand,
among  p53  immunonegative  patients,  one
patient died at 15 months and 9 patients were
alive  at  a  median  follow  up  of  22  months
(range  1-24).  The  difference  between  these
two  groups  did  not  reach  statistical  signifi-
cance (P=0.60, log rank test).
Bcl-2 protein expression and survival
Among the 110 patients, 96 (87%) were Bcl-
2  immunopositive  while  14  (13%)  patients
were  Bcl-2  immunonegative.  Of  the  Bcl-2
immunopositive  cases,  10  (9.09%)  included
only a small percentage (1-10%) of Bcl-2 posi-
tive cells, 24 (21.81%) had low intermediate
(11-30%),  20  (14%)  had  high  intermediate
(31-50%) and 42 (51%) had highly expressed
(>50%) Bcl-2 immunopositive leukemic cells. 
A comparison of Bcl-2 positive vs negative
subgroups  did  not  reach  statistical  signifi-
cance  (P=0.24,  log  rank  test,  Figure  1B).
Kaplan-Meier curves showed that overall sur-
vival was shorter in subgroups +1 and +4. The
log rank test showed a statistically significant
difference  in  clinical  outcome  between  sub-
groups:  +1  vs +2,  P=0.0558;  +2  vs +4,
P=0.0246; +3 vs +4; P=0.0021. However, there
was  no  statistically  significant  difference
between  subgroup  +1  vs +3  (P=0.1729)  or
subgroup +2 vs +3 (P=0.3799). Multivariate
analysis showed that Bcl-2 immunopositivity
(>10%) was associated with a longer overall
survival (P=0.002). 
Among  96  Bcl-2  immunopositive  patients
who  were  also  p53  immunopositive,  5  died
within 1-20 months (median 11) and 91 were
alive  at  a  median  follow  up  of  22  months
(range 1-24). On the other hand, among Bcl-2
negative  patients,  one  patient  died  at  12
months and 13 patients were alive at a median
follow up of 18 months (range 1-24). There
was  no  statistically  significant  difference
between  the  two  groups  (P=0.24,  log  rank
test).
Correlation of Bcl-2 with prognos-
tic parameter
We  examined  the  possible  association  of
Bcl-2 protein expression in primary leukemic
cells  of  AML  patients  and  their  clinical  fea-
tures. Both age and WBC, which were predic-
tive of poor outcome, were associated with a
high level of Bcl-2 expression. Leukemic cells
from patients with a WBC of 50¥109/L or more
showed significantly higher Bcl-2 levels than
leukemic cells from patients with a WBC of
less  than  50¥109/L.  Age  between  40  and  60
years was associated with high Bcl-2 expres-
sion.  Leukemic  cells  of  patients  with
splenomegaly  or  hepatomegaly  expressed  a
high level of Bcl-2.
Discussion 
p53 and Bcl-2 immunostaining data of AML
patients were evaluated to establish a possible
correlation  with  overall  survival  outcome
(Tables 1 and 2). For example, patients whose
leukemic cells were p53 immunonegative and
Bcl-2 immunonegative were associated with a
longer overall survival. Steven et al.28 reported
the correlation between Bcl-2 immunopositive
data with clinical outcome and showed longer
overall survival in Bcl-2 immunopositive cases.
The reason for this is that Bcl-2 and wild-type
p53  are  commonly  expressed  in  normal  B
cells.29,30 Conflicting data were obtained by dif-
ferent authors regarding p53 and Bcl-2 expres-
sion  with  respect  to  survival  analysis.  We
observed  that  p53  immunopositive  leukemic
cells (≤10%) were associated with improved
survival but Karkas et al.16 reported that the
patients in their study with p53 immunoposi-
tivity had a higher percentage of blast cells,
leukocytes and platelets counts, but that these
had no influence on the complete remission
rate.  Similar  to  other  studies,12,13,15,16,30-32
expression of Bcl-2 was observed in most of
the AML samples and median levels of Bcl-2
expression did not vary. The heterogeneity of
expression  was  similar  among  FAB  types.
Acute  promyelocytic  leukemia  cases  were
observed  to  have  strong  expression  of  Bcl-2
compared  to  0,  60%,  and  75%  reported  by
Campos et al.,12 Bankar et al.33 and Karakas et
al.,16 respectively.  All  previous  reports  agree
with this present study in that there is a wide
degree of heterogeneity in the expression of
Bcl-2 in AML patients. In our study, high Bcl-2
expression was an adverse prognostic factor
for both survival and event-free survival, and
was  significant  as  a  prognostic  factor  for
remission duration. This finding is similar to
those of other workers.12,13,15,16 Karkas et al.16
have reported that the adverse effect of high
Bcl-2  was  more  prominent  in  patients  aged
over 60. The report by Lauria et al.15 did not
show  the  effect  of  Bcl-2  level  on  survival,
although high Bcl-2 level was associated with a
lower complete remission rate. 
Campos et al.12 reported overexpression of
Bcl-2 was correlated with poor treatment out-
come in AML patients. Our results showed sta-
tistically  significant  correlations  in  Bcl-2
immunopositive cases (P=0.0038) in univari-
ate  analysis,  while  in  multivariate  analysis
prognostic  factors  such  as  age  at  diagnosis,
gender,  WBC  count,  platelet  count,  spleno  -
megaly,  hepatomegaly  and  serum  LDH  were
associated  with  longer  overall  survival
(P=0.002). To assess the importance of Bcl-2
expression in pediatric AML, we found a corre-
lation between clinical outcome and level of
Bcl-2  protein  expression.  The  correlation  of
this with patient response to chemotherapy or
long-term  outcome  did  not  reach  statistical
significance, which was similar to the findings
of other workers.31 High levels of Bcl-2 would
allow a cell to escape or suppress apoptotic sig-
nals, including those induced by chemothera-
py. Banker et al.33 reported a higher percent-
age of patients expressing high levels of Bcl-2
at relapse and this difference was not always
statistically significant, as reported by Bense et
al.34 We observed that a low level of Bcl-2 was
associated with lower response rates, shorter
remission  duration  and  inferior  survival.  A
lower level of Bcl-2 was an independent prog-
nostic factor for both survival and remission
duration.  Karakas  et  al.16 reported  that
patients with high Bcl-2 level had a better com-
plete remission rate (63 vs 51%). Lepelley et
al.35 reported Bcl-2 levels in MDS patients and
observed that high Bcl-2 was a favorable prog-
nostic finding. In the study by Maung et al.,13
none of the patients with secondary leukemia
and lower levels of Bcl-2 expression achieved
CR.  However,  this  cannot  be  compared  with
Article
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Table 2. P53 and BCL-2 immuno-scoring and survival data of AML patients.
P53 immunoscore N. (%) BCL-2  N. (%) FAB  N. (%) Survival
immunoscore subtypes (range in
months)
Negative 10 (9.09) Negative 14 (12.72) M1 32 (29.09) 18-24
1-10% 6 (5. 45) 1- 10% 10 (9.09) M2 32 (29.09) 14-20
11-30% 22 (20) 11- 30% 24 (21.81) M3 24 (21.81) 15-18
31-50% 16 (14. 54) 31-50% 20 (18.18) M4 18 (16.36) 9-14
>50% 56 (50.9) >50% 42 (38.18) M5 4 (3.63) 5-9
Total:  110 Total 110 Total 110
Number of samples with the indicated p53 and Bcl-2 scores of <1% (negative), 1-10%, 11-30%, 31-50% and > 50%.[page 94] [Hematology Reports 2011; 3:e28]
the present study due to the small sample size
and low remission rate. From our study, it is
clear that the Bcl-2 protein expression is sig-
nificantly  higher  than  in  normal  controls,
which is consistent with other reports.36 This
indicates  that  the  alteration  of  Bcl-2  is  an
important  mechanism  in  the  pathogenesis,
progress and the development of drug resist-
ance in AML. Bcl-2 might have a different role
in disease pathogenesis and leukemic progres-
sion, thus giving different prognostic implica-
tions to the same level of expression. This dis-
tinction  could  have  important  therapeutic
implications for future therapies designed to
induce apoptosis or block anti-apoptotic pro-
teins. A recent clinical trial studied antisense
deoxyoligonucleotides  for  Bcl-2.37 AML
patients may, therefore, show a mechanism of
protein  stabilization  and  this  has  been
observed in interactions with viral or other cel-
lular  proteins.38,39 Alternatively,  in  these
patients  our  observations  may  represent  a
high  level  of  constitutive  expression,  which
has been reported previously.38
In  summary,  statistical  analysis  showed  a
significant correlation between p53 and Bcl-2
protein. Therefore, these two apoptotic-regu-
lating proteins may be considered prognostic
marker for acute myeloid leukemia.
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